| Literature DB >> 31030807 |
Carolyn Hoppe1, Lynne Neumayr2.
Abstract
Screening and early detection of organ injury, as well as expanded use of red cell transfusion and hydroxyurea in children have changed best practices for clinical care in sickle cell disease. The current standard of care for children with sickle cell disease is discussed through a review of screening recommendations, disease monitoring, and approach to treatment. Novel pharmacologic agents under investigation in clinical trials are also reviewed.Entities:
Keywords: Hydroxyurea; Novel therapeutics; Screening; Sickle cell disease; Treatment
Mesh：
Substances：
Year: 2019 PMID： 31030807 DOI： 10.1016/j.hoc.2019.01.014
Source DB: PubMed Journal: Hematol Oncol Clin North Am ISSN： 0889-8588 Impact factor: 3.722